Market Intelligence, Clinical Progress, and High-Purity Reagents for Chromosomal Instability-Targeted Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KIF18A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KIF18A Motor Domain Recombinant Protein (WT & Mutant) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. ATP-binding competent. |
View KIF18A Products |
| Gene Delivery | KIF18A Promise-ORF / Lentivirus Full-length ORF for stable cell lines. CMV promoter, Puromycin selection. Rescue assay compatible. |
View KIF18A Products |
| Benchmark Ab | Anti-KIF18A (Recombinant Clone for ICC/Western) Sequence Verified. Recombinant positive control. |
View KIF18A Products |
| Validator | KIF18A siRNA Set For knockdown verification and specificity controls in CIN-high cell lines (e.g., HCT116, MDA-MB-231). |
View KIF18A Products |
| Related Target A | KIF11 (Eg5) Off-target comparator for kinesin selectivity panel; paralog for selectivity testing. |
View KIF11 Products |
| Related Target B | KIFC1 Counter-screening kinesin family member; essential for cross-reactivity profiling. |
View KIFC1 Products |
| Related Target C | KIF20A (MKLP2) Related mitotic kinesin; important for dual-target strategies and cross-reactivity checks. |
View KIF20A Products |
| Related Target D | TP53 Biomarker for chromosomal instability (CIN) status stratification; mutation status linked to synthetic lethality. |
View TP53 Products |
| Related Target E | PLK1 Synergistic pathway partner in mitotic regulation; combination therapy research. |
View PLK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Off-target kinesin inhibition (KIF11, KIFC1, KIF20A) | Homolog panel proteins (KIF11, KIFC1, KIF20A) strictly verified by Sequence & Theoretical MW; >95% purity for clean SAR. |
| Drug resistance mutation mapping | Custom mutant KIF18A motor domain proteins available (e.g., G225D, R308H, E301K; also covering dbSNP variants rs12272419, rs34913484, rs10458896). Sequence Verified by Mass Spec, HEK293 expressed for native folding. |
| High-Throughput Screening Compatibility | High purity (>95%), Endotoxin <1EU/µg, Lot-to-lot consistency for cellular proliferation assays. |
| Lack of Assay Controls | Clinical Benchmark Antibodies and high-specificity siRNA set included for on-target validation. |
| False Positives in cellular assays | Validated siRNA and Rescue ORF Lentivirus for rigorous target specificity checks. |
Live KIF18A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KIF18A therapeutics is intensifying, with major players shifting focus from broad-spectrum anti-mitotics to precision synthetic lethal strategies exploiting chromosomal instability (CIN). First-generation inhibitors (e.g., Amgen's MSC-110/AMG 650, AstraZeneca's AZD-4785 siRNA) are advancing through Phase I/II trials in CIN-high solid tumors (ovarian, breast, gastric, NSCLC). Unlike previous anti-mitotics that caused neutropenia, KIF18A inhibition offers a therapeutic window via CIN-dependent synthetic lethality. The next wave of R&D is targeting biomarker-driven patient stratification (TP53 mutation, CIN70 score) and rational combination regimens with DNA damage response inhibitors (PARP inhibitors) and microtubule-targeting agents, as well as overcoming acquired resistance mutations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Amgen (MSC-110), Volastra Therapeutics, Treadwell Therapeutics | Ovarian, Breast, Gastric, NSCLC (CIN-high) | ATPase & Microtubule Binding Assay (Need high-purity Motor Domain proteins) |
| siRNA / ASO | AstraZeneca (AZD-4785), Silence Therapeutics | Solid Tumors | Lentiviral shRNA validation systems (Stable knockdown cell lines) |
| PROTAC / Degrader | Emerging Biotech | Refractory Cancers | Degradation Validation (Need specific Abs & stable cell lines) |
| Combination Therapy | Academic / Pharma Consortia | Solid Tumors (TP53-mutant, CIN-high) | Cell line rescue / Overexpression (Need Lentivirus ORF & siRNA) |
| Diagnostic Companion | CIN-score Developers | Tumor Agnostic (CIN-high) | Target Validation Reagents (Need Anti-KIF18A Antibodies & siRNA) |
| Mutant Resistance Panel | Multiple Academic Labs | Refractory CIN-high tumors | Mutant vs WT Protein Selectivity Assay (Need G225D, R308H variants) |